Shanghai Bao Pharmaceuticals Co Ltd Class H

As of December 31, 2025, Shanghai Bao Pharmaceuticals Co Ltd Class H carries a market capitalization of 25.28B, placing it among publicly traded companies globally. Its enterprise value stands at 24.15B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shanghai Bao Pharmaceuticals Co Ltd Class H's next confirmed earnings release is scheduled for March 26, 2027.

As of December 31, 2025, Shanghai Bao Pharmaceuticals Co Ltd Class H has 325.98M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Shanghai Bao Pharmaceuticals Co Ltd Class H maintains a current ratio of 4.12, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 13.83, while the 200-day moving average is 53.61.

As of December 31, 2025, Shanghai Bao Pharmaceuticals Co Ltd Class H holds 1.48B in cash and equivalents against 350.56M in total debt, resulting in a net debt position of -1.13B. Total book value stands at 1.77B, with working capital of 1.15B providing operational flexibility.